This is a working overview of growth hormone secretagogue, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-10-23. Anything still debated is marked as such rather than presented as settled.
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic pentapeptide | GHS-R1a agonist family |
| Receptor target | Ghrelin receptor (GHS-R1a) | G-protein-coupled receptor |
| Sequence length | Five amino acid residues | Includes non-natural residues |
| Primary reported output | Pulsatile growth hormone release | Observed in animal and early human work |
| Molecular formula | C38H49N9O5 | Corresponds to roughly 711.9 g/mol |
At the cellular level, ipamorelin binds the growth hormone secretagogue receptor, also called the ghrelin receptor. Activation of this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to release of growth hormone into circulation. Because release follows a pulsatile pattern, studies often report peak concentration and total area under the curve rather than a single time point. Selectivity for this receptor is the property most frequently discussed in comparative work.
Compared with older secretagogues such as hexarelin or GHRP-6, ipamorelin shows weaker stimulation of cortisol, prolactin, and appetite in the animal models used for early characterization. Whether that selectivity is preserved across longer human exposures remains an open question, because published clinical data are limited in size and duration. Reported effects on food intake are generally described as modest. The compound is therefore treated in the literature as a relatively selective research tool rather than a fully characterized therapeutic agent.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Researchers at a pharmaceutical company first described it in the 1990s while screening small peptides for growth hormone releasing activity. Its chain contains five amino acid residues, two of which are non-natural building blocks, including 2-aminoisobutyric acid and a naphthylalanine derivative. The molecule was designed to act at the ghrelin receptor while avoiding several effects observed with earlier secretagogues.
Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
=== Development === In November 1990, Warner Bros. Pictures purchased the film rights to "The Rest of Daniel" for $2 million, the most ever paid for a screenplay. Originally intended as a star vehicle for Gibson, he declined the opportunity to direct the feature. The film formed part of a multi-million-dollar three-year distribution deal he signed with Warner Bros., which also guaranteed him a minimum of three months off a year to spend with his family.
Chronic overdose masked by Somogyi: A dose that is too high may cause a Somogyi rebound, which can look like a need for more insulin. This condition can continue for days or weeks. High-carbohydrate cat food: Many commercial foods (especially "light" foods) are very high in carbohydrates. The extra carbohydrates keep the cat's blood sugar high. In general, canned foods are lower in carbohydrates than dry foods, and canned "kitten" foods lower still. Diabetes in cats can be better regulated and even sometimes reversed with a low-carbohydrate diet. Inappropriate insulin: Different brands and types of insulin have idiosyncratic effects on different cats. With some dosages, the insulin may not last long enough for the cat. Testing blood sugar more frequently can determine if the insulin is controlling the blood sugar concentration throughout the day.
Methanobactin (mb) is a class of copper-binding and reducing chromophoric peptides initially identified in the methanotroph Methylococcus capsulatus Bath - and later in Methylosinus trichosporium OB3b - during the isolation of the membrane-associated or particulate methane monooxygenase (pMMO). It is thought to be secreted to the extracellular media to recruit copper, a critical component of methane monooxygenase, the first enzyme in the series that catalyzes the oxidation of methane into methanol. Methanobactin functions as a chalkophore, similar to iron siderophores, by binding to Cu(II) or Cu(I) then shuttling the copper into the cell. Methanobactin has an extremely high affinity for binding and Cu(I) with a Kd of approximately 1020 M−1 at pH 8. Additionally, methanobactin can reduce Cu(II), which is toxic to cells, to Cu(I), the form used in pMMO. Moreover, different species of methanobactin are hypothesized to be ubiquitous within the biosphere, especially in light of the discovery of molecules produced by other type II methanotrophs that similarly bind and reduce copper (II) to copper (I).
=== Digital circuitry === One-hot encoding is often used for indicating the state of a state machine. When using binary, a decoder is needed to determine the state. A one-hot state machine, however, does not need a decoder as the state machine is in the nth state if, and only if, the nth bit is high. A ring counter with 15 sequentially ordered states is an example of a state machine. A 'one-hot' implementation would have 15 flip-flops chained in series with the Q output of each flip-flop connected to the D input of the next and the D input of the first flip-flop connected to the Q output of the 15th flip-flop. The first flip-flop in the chain represents the first state, the second represents the second state, and so on to the 15th flip-flop, which represents the last state. Upon reset of the state machine all of the flip-flops are reset to '0' except the first in the chain, which is set to '1'. The next clock edge arriving at the flip-flops advances the one 'hot' bit to the second flip-flop. The 'hot' bit advances in this way until the 15th state, after which the state machine returns to the first state. An address decoder converts from binary to one-hot representation. A priority encoder converts from one-hot representation to binary.
== Essendon Football Club == Reid joined Essendon Football club in 1982 shortly after Kevin Sheedy, a player at Richmond, had joined as coach. From this time until his cancer diagnosis in 2018, he served as senior medical officer for Essendon.
Sources: en.wikipedia.org
Brimonidine is an α2 agonist medication used to treat open-angle glaucoma, ocular hypertension, and rosacea. In rosacea it improves the redness. It is used as eye drops or applied to the skin. It is also available in the fixed-dose combination medication brimonidine/timolol along with timolol maleate. Common side effects when used in the eyes include itchiness, redness, and a dry mouth. Common side effects when used on the skin include redness, burning, and headaches. More significant side effects may include allergic reactions and low blood pressure. Use in pregnancy appears to be safe. When applied to the eye it works by decreasing the amount of aqueous humor made while increasing the amount that drains from the eye. When applied to the skin it works by causing blood vessels to contract. Brimonidine was patented in 1972 and came into medical use in 1996. It is available as a generic medication. In 2023, it was the 213th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
In October 2018, Reitan Convenience, a division of Reitan AS, acquired the chain, with the founding team remaining in management. Soon after, the brand was shortened to Caffeine and integrated into the group's wider convenience formats. The concept expanded beyond the Baltics, with cafés opening in Oslo and Copenhagen. In 2022 the chain switched all Baltic outlets to serving only certified organic beans, becoming the first in the region to do so.By 2025 Caffeine operated more than 100 cafés in Lithuania, including a new drive-through and charging hub in Varėna. The chain also ran 27 cafés in Latvia and 12 in Estonia.
=== Health Risks === Studies show that xenografts can be used, however they are closely monitored due to their risk of rejection. Zoonoses, which are diseases that arise from the crossing of animal and human tissue, pose a threat to the success of xenograft implantation. Specifically, these diseases are referenced as "xenozoonoses". They can be categorized in 3 different groups: viral infection, prion-mediated infection, and bacterial infection. They have the potential to create a public health risk if they are not closely monitored, as they can cause diseases to be more easily transmissible through different species.
==== Air via nasogastric tube ==== Several neonatologists have described the allegation that Letby murdered three infants by injecting air into their stomachs via a nasogastric tube as implausible, variously calling the theory "nonsensical", "ridiculous", "fantastical" and "not practically feasible". An X-ray heavily relied upon by the prosecution in relation to Child C was taken when Letby had not been on shift since the infant's birth. Following the trial, the prosecution's lead medical witness, Dr Dewi Evans, subsequently stated that he had changed his opinion regarding the cause of Baby C's death. He no longer believed that the air in Baby C's stomach, which he had told the jury had caused the infant's collapse, was responsible for his death. Instead, Evans said that the stomach bubble was not responsible for the death and that Baby C died later, as a result of air entering the bloodstream. He therefore altered his view of the precise physiological mechanism by which Baby C died, while continuing to maintain that Letby was responsible for Baby C's death. The Lee panel concluded that there was no evidence that air had been forced down any infant's nasogastric tube.
Sources: en.wikipedia.org
It is a synthetic pentapeptide in the growth hormone secretagogue family and acts as an agonist at the ghrelin receptor. It is handled as a laboratory research compound rather than a naturally occurring hormone.
Studies generally report growth hormone as the dominant output, with smaller or absent effects on adrenocorticotropic hormone and prolactin. The size of that separation depends on the assay and the dose examined, so it is best described as relative selectivity.
No natural source has been identified, and the molecule is produced by chemical synthesis. Its non-natural residues distinguish it from endogenous ghrelin even though both engage the same receptor.
It is a synthetic pentapeptide belonging to the growth hormone secretagogue family. Its principal characterized target is the ghrelin receptor, also called GHS-R1a. The molecule contains non-natural amino acids and an amidated C-terminus.